口服孟鲁司特治疗咳嗽变异性哮喘的疗效观察

Observation on efficacy of oral montelukast on cough variant asthma

目的观察孟鲁司特治疗咳嗽变异性哮喘(CVA)的临床疗效。方法 60例咳嗽变异性哮喘患者,随机分为对照组与观察组,各30例。对照组给予吸入布地奈德福莫特罗吸入剂治疗,观察组给予口服孟鲁司特治疗。治疗4周后,比较两组患者临床症状体征情况(包括哮喘持续时间、咳嗽消失时间、肺部哮鸣音消失时间)及治疗前后生活质量评分。结果治疗后两组患者的哮喘持续时间、咳嗽消失时间、肺部哮鸣音消失时间比较差异无统计学意义(P>0.05);治疗前,对照组患者莱切司特咳嗽问卷(LCQ)评分为(9.49±1.51)分,观察组患者LCQ评分为(9.52±1.46)分,两组比较差异无统计学意义(P>0.05)。治疗4周后,对照组患者LCQ评分为(13.78±1.87)分,观察组患者LCQ评分为(14.13±1.95)分,两组较治疗前显著提高,差异具有统计学意义(P<0.05);两组比较差异无统计学意义(P>0.05)。结论口服孟鲁司特与吸入布地奈德福莫特罗吸入剂在治疗咳嗽变异性哮喘上疗效相当,由于孟鲁司特具有口服制剂给药方便、患者依从性好、临床管理准确且方便等优势,更适合在临床上推广使用。

Objective To observe the clinical efficac of montelukast on the treatment of cough variant asthma (CVA). Methods A total of 60 patients with cough variant asthma were randomly divided into control group and observation group, with 30 cases in each group. The control group was treated with budesonide formoterol powder inhaler, and the observation group was treated with oral montelukast. After 4 weeks of treatment, clinical symptoms and signs (including asthma duration, cough disappearance time, lung wheezing disappearance time) and quality of life scores before and after treatment were compared between the two groups. Results After treatment, both groups had no statistically significant difference in asthma duration, cough disappearance time, lung wheezing disappearance time (P>0.05). After treatment, the control group had leicester cough questionnaire (LCQ) score as (9.49±1.51) points, which was (9.52±1.46) points in the control group, and both groups had no statistically significant difference (P>0.05). After 4 weeks of treatment, the control group had LCQ score as (13.78± 1.87) points, which was (14.13±1.95) points in the observation group. Both groups had significantly higher points than those before treatment, and the differences were statistically significant (P<0.05). Both groups had no statistically significant difference (P>0.05). Conclusion Oral montelukast and budesonide formoterol powder inhaler are equally effective in the treatment of cough variant asthma, because montelukast has the advantages of convenient oral administration, good patients’compliance, accurate and convenient clinical management. It is more suitable for clinical promotion and application.